The 0.3 mL syringe holds 30 units and offers the finest precision for small doses
Key regulatory points for Epitalon Australia compliance: Epitalon is not approved by the Therapeutic Goods Administration (TGA) as a registered medicine for human or veterinary use It is classified strictly for laboratory and research purposes, not for human consumption Supply, import, and handling of research peptides fall under Australian regulatory oversight, and institutions should confirm current scheduling status directly through TGA resources before procurement Any research involving human subjects must comply with Research Ethics Committee approval and applicable Good Clinical Practice standards Marketing or supplying Epitalon with therapeutic claims, or implying suitability for human treatment, falls outside permitted research-use classifications Researchers and institutions should treat Epitalon strictly as a laboratory reagent, ensuring internal documentation, handling protocols, and communications consistently reflect its research-only status
Reported concerns include local injection reactions, potential immunogenicity from copper exposure with chronic use, and theoretical risks if peptides activate unintended growth pathways
The best approach for post-weight-loss skin is injectable GHK-Cu for systemic collagen and elastin stimulation, optionally combined with topical GHK-Cu serum on targeted areas for additional surface-level benefits
